Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-00101 (HSP-E7) for CIN II/III
NCT00060099Phase 2Unknown
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2003
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of verpasep caltespen in cervical intraepithelial neoplasia (CIN), sponsored by Dana-Farber Cancer Institute. Status: unknown.
02
Drugs
verpasep caltespen
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00060099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060099.